Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone

Small, Eric J.; Meyer, Mark; Marshall, M. Ernest; Reyno, Leonard; Meyers, Frederick J.; Natale, Ronald B.; Lenehan, Peter F.; Chen, Liang; Slichenmyer, William J.; Eisenberger, Mario A.

doi:10.1200/jco.2000.18.7.1440

Cited by 165 publications

(82 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Verification of this assay system is supported by our data showing VEGF significantly increased angiogenesis in this assay while suramin inhibited angiogenesis by approximately 50%. Suramin is an established anti-angiogenic agent and has been used to treat patients with various cancers (Stein et al, 1989;Danesi et al, 1993;Small et al, 2000). Therefore, the anti-angiogenic potency of these compounds suggests that they may be of improved therapeutic value.…”

Section: Discussionmentioning

confidence: 99%

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

et al. 2002

View full text Add to dashboard Cite

The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties. Second generation thalidomide analogues are distinct compounds with enhanced therapeutic potential. Although these compounds are beginning to enter trials for the treatment of cancer there is very little information regarding the anti-angiogenic activity of these clinically relevant compounds. Furthermore, it is not known how the various immunomodulatory activities of these compounds relate to anti-angiogenic activity. In this study we assessed the anti-angiogenic activity of compounds from both IMiD TM and SelCID TM classes of analogues using a novel in vitro multicellular human assay system and the established rat aorta assay. Our results show that both the IMiDs and SelCIDs tested are significantly more potent than thalidomide. The anti-angiogenic potency of the analogues was not related to inhibition of endothelial cell proliferation, nor their TNF-a/PDE type 4 inhibitory properties. However, anti-migratory effects in vitro and inhibition of tumour growth in vivo was observed with the analogue IMiD-1 (clinically known as REVIMID TM ). Our results show that anti-angiogenic activity spans both currently defined classes of thalidomide analogue and is not related to their previously described immunomodulatory properties. Identification of the differential effects of these compounds will enable targeting of such compounds into the appropriate clinical setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

et al. 2002

View full text Add to dashboard Cite

show abstract

“…26,27,35,36,39,44,46 This measure, specifically validated on advanced metastatic prostate patients, consists of 30 questions addressing 10 relevant do- 31 the Functional Living Index-Cancer, 45 the Southwest Oncology Group questionnaire (SWOG), 29 and the Functional Assessment of Cancer Therapy. 32 Nevertheless, some trials reported limited information about the nature of the HRQOL measure used while others created ad hoc measures without giving any information about the developmental process. 25,38,48,49 …”

Section: Hrqol Assessment Methodologymentioning

confidence: 99%

“…Ten RCTs were carried out in North America, [25][26][27][28][29][30][31][32][33][34] nine were carried out in Europe, [35][36][37][38][39][40][41][42][43] three enrolled patients from different continents, 44 -46 and three were carried out in Japan. [47][48][49] Bicalutamide, the therapy against which most treatment comparisons were made, was used in seven trials.…”

Section: Demographics and Trial Designsmentioning

confidence: 99%

Health related quality of life in prostate carcinoma patients

Efficace

Bottomley

Andel

2003

Cancer

View full text Add to dashboard Cite

Extensive lattice‐Boltzmann simulations were performed to obtain the drag force for random arrays of monodisperse and bidisperse spheres. For the monodisperse systems, 35 different combinations of the Reynolds number Re (up to Re = 1,000) and packing fraction ϕ were studied, whereas for the bidisperse systems we also varied the diameter ratio (from 1:1.5 to 1:4) and composition, which brings the total number of different systems that we considered to 150. For monodisperse systems, the data was found to be markedly different from the Ergun equation and consistent with a correlation, based on similar type of simulations up to Re = 120. For bidisperse systems, it was found that the correction of the monodisperse drag force for bidispersity, which was derived for the limit Re = 0, also applies for higher‐Reynolds numbers. On the basis of the data, a new drag law is suggested for general polydisperse systems, which is on average within 10% of the simulation data for Reynolds numbers up to 1,000, and diameter ratios up to 1:4. © 2007 American Institute of Chemical Engineers AIChE J, 2007.

show abstract

“…Better assessment of the role of glutocorticoids alone can be obtained from the larger randomised phase III trials that included prednisone or hydrocortisone alone as a control arm. In these studies, the rate of PSA response was in the range 16 -24%, and generally of short duration (Tannock et al, 1996;Kantoff et al, 1999;Small et al, 2000b;Berry et al, 2002). In symptomatic patients, prednisone or hydrocortisone treatment was inferior in improving pain and other symptoms to arms that included mitoxantrone and steroid.…”

Section: Glucocorticoidsmentioning

confidence: 99%

Is there a role for chemotherapy in prostate cancer?

Canil

Tannock

2004

Br J Cancer

View full text Add to dashboard Cite

There is evidence from randomised-controlled trials that patients with symptomatic hormone-refractory prostate cancer may experience palliative benefit from chemotherapy with mitoxantrone and prednisone. This treatment is well tolerated, even by elderly patients, although the cumulative dose of mitoxantrone is limited by cardiotoxicity. Treatment with docetaxel or paclitaxel, with or without estramustine, appears to convey higher rates of prostate-specific antigen response in phase II trials, but is more toxic. Large phase III trials comparing docetaxel with mitoxantrone have completed accrual. There is no role for chemotherapy in earlier stages of disease except in the context of a well-designed clinical trial. Chemotherapy has not been shown to alter survival in prostate cancer. However, in recent years, clinical trials have provided evidence for a palliative role of chemotherapy in patients with symptomatic hormone-refractory disease. In addition, new chemotherapeutic agents have shown promising results in phase II studies leading to enthusiasm for challenging the belief that chemotherapy does not alter the natural history of prostate cancer. In this article, we will review the role of chemotherapy during various stages of prostate cancer, using hypothetical case reports to illustrate our evidence-based discussion.

show abstract

Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone

Abstract: Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.

Cited by 165 publications

References 29 publications

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

Health related quality of life in prostate carcinoma patients

Is there a role for chemotherapy in prostate cancer?

Contact Info

Product

Resources

About